18. The method of claim 14 or claim 16 that is a batch crystallization method.

19. The method of claim 16, wherein the crystallization reagent comprises

(a) about 1 M succinic acid, about 0.1 M HEPES and about 1% (w/v) polyethylene glycol monomethyl ether 2000;

(b) about 10% (w/v) PEG-8000, about 0.1 M imidazole and about 0.2 M calcium acetate;

(c) about 20% (w/v) PEG-1000, about 0.1 M sodium/potassium phosphate and about 0.2 M sodium chloride;

(d) about 14.4% (w/v) PEG-8000, about 0.08 M cacodylate, about 0.16 M calcium acetate, and about 20% (w/v) glycerol; or

(e) about 19.9% isopropanol and about 0.2 M sodium/potassium phosphate.

~~20. An antibody crystal produced by the method of claim 14 or claim 16.~~

~~21~~20. Use of the formulation of any one of claims 1 and 7-13 in the manufacture of a medicament for increasing bone mineral density, treating a disorder associated with decreased bone density, treating a bone-related disorder, or improving outcomes in a procedure, replacement, graft, surgery or repair in a mammalian subject, wherein said formulation is to be provided in an amount effective to increase bone mineral density in the subject.